Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China flag China · Delayed Price · Currency is CNY
1.280
+0.020 (1.59%)
Oct 30, 2026, 3:00 PM CST

Kangmei Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
90.6510.338.57102.52-2,6887,918
Depreciation & Amortization
303.98306.37339.99346.18365.69603.22
Other Amortization
28.1625.7733.4222.4927.7335.19
Loss (Gain) From Sale of Assets
-0.85-0.85-39.47-19.61-0.98-64.01
Asset Writedown & Restructuring Costs
85.2285.2231.4799.97307.462,643
Loss (Gain) From Sale of Investments
-90.61-90.61-59.18-44.4-0.75-188.79
Provision & Write-off of Bad Debts
56.4156.4124.89-238.47213.411,192
Other Operating Activities
-81.7138.61114.76196.51278.142,577
Change in Accounts Receivable
-128.26-128.26-502.64215.15-339.53-746.88
Change in Inventory
96.0596.05-34.32-93.01-253.621,666
Change in Accounts Payable
-290.34-290.34-347.41-896.421,321-15,587
Change in Other Net Operating Assets
-----0.59
Operating Cash Flow
71.35111.35-427.63-317.52-749.96214.21
Operating Cash Flow Growth
19.11%-----79.23%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-186.51-217.06-61.71-99.74-48.12-171.63
Sale of Property, Plant & Equipment
22.5539.79164.3352.251.5577.9
Divestitures
--27.39.85-57.72
Investment in Securities
------0.53
Other Investing Activities
-3.57-10-0.550.04
Investing Cash Flow
-167.54-177.27139.92-37.64-46.02-36.51

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
--0.1--127.64
Total Debt Issued
1-0.1--127.64
Short-Term Debt Repaid
--43.5-0.1---97.03
Long-Term Debt Repaid
--43.33-54.36-72.71-94.95-48.66
Lease Payments
-43.33-43.33-51.86-58.58-53.33-48.66
Total Debt Repaid
-43.33-86.83-54.46-72.71-94.95-145.69
Net Debt Issued (Repaid)
-42.33-86.83-54.36-72.71-94.95-18.05
Issuance of Common Stock
-----1,800
Common Dividends Paid
-0.01----0.9-13.82
Dividends Paid
-0.01----0.9-13.82
Other Financing Activities
288.35376.08229.18-48.14-21.010.25
Financing Cash Flow
246.01289.25174.81-120.85-116.861,768

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.04-0.01-000-0.04
Net Cash Flow
149.78223.31-112.91-476.01-912.841,946

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-115.16-105.71-489.34-417.27-798.0842.58
Free Cash Flow Growth
------94.16%
Free Cash Flow Margin
-2.39%-2.01%-9.43%-8.56%-19.09%1.03%
Free Cash Flow Per Share
-0.01-0.01-0.03-0.04-0.060.00
Levered Free Cash Flow
-382.73-222.11-313.11,126117.24-6,029
Unlevered Free Cash Flow
-374.15-210.44-299.731,161166.55-5,391
Free Cash Flow After Leases
-158.49-149.04-541.2-475.84-851.41-6.08

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
----1.06-
Cash Income Tax Paid
158.72155.54295.28211.36284.45235.31
Change in Working Capital
-319.91-319.91-882.08-782.71747.5-14,501